Slide Left Slide Right
Accelmed invests in private and public medical device companies around the world
Accelmed merges global businesses with promising medical device start-ups, creating significant revenue growth
Accelmed’s platform model has proven to provide high returns to investors, managers and entrepreneurs
Accelmed invests in private and public medical device companies around the world
Accelmed merges global businesses with promising medical device start-ups, creating significant revenue growth
Accelmed’s platform model has proven to provide high returns to investors, managers and entrepreneurs
Accelmed invests in private and public medical device companies around the world
Accelmed merges global businesses with promising medical device start-ups, creating significant revenue growth
Accelmed’s platform model has proven to provide high returns to investors, managers and entrepreneurs
 
 
 
 
 

 

Merging Med-Tech innovation with global commercial platforms 

 

Accelmed is an investment firm focused on value creation for medical device companies and technologies. Accelmed was founded in 2009 by Mori Arkin and Uri Geiger and has invested over the past years in nearly 20 small and mid-cap private and public companies.

With its proven track record and large team of accomplished investment professionals, Accelmed’s vision is to create leading med-tech players by merging commercial platforms with small innovative growth companies, predominantly from Israel.

 

 

 

 

 

 
 
 
 
 

 

Integrating commercial platforms with innovation and providing growth equity to foster significant value creation

 

Accelmed brings its acumen in medical devices and its dominant presence in Israel to the Platform Model, which has already been implemented with great success.

Under the Platform model, Accelmed integrates innovative and market-ready medical device technologies into existing commercial companies that are able to effectively distribute and commercialize the new products.

Accelmed makes significant equity investments – or a combination of equity and debt – of between $20M and $50M per platform. In certain cases, in combination with its co-investing partners, investment can be increased to up to $300M.

We intend to acquire a significant interest in established medical device companies (in the US, Europe and potentially in China) with revenues in excess of $30M and which have an experienced direct sales force.

 

Accelmed_Growth_Partners

 

Proceeds of our investments will be used for both organic and inorganic growth through the acquisition and integration of innovative market ready medical device technologies identified and selected by Accelmed and the platform company management.

The acquired Israeli start-ups will serve as ongoing sources for cost-efficient R&D as, based on Accelmed’s proven experience with Israeli R&D teams,  they are not only innovative but also operate in a faster and more efficient way than their peers overseas.

 

 

Platform Case Studies

Endochoice – Platform Model Case Study

The Platform Model modus operandi is best illustrated through the merger between Peer Medical, an Accelmed portfolio company and developer of the Full Spectrum Endoscope, and EndoChoice, a gastroenterology (GI) player in Atlanta, GA, which had a solid commercial infrastructure but which lacked innovative products.

By merging Peer into EndoChoice and the addition of working capital, Accelmed was able to transform EndoChoice from a commodity player into a cutting edge technology company. The merger, carried out in 2013, led to Endochoice’s emergence as a leading, global, GI player with sales above $60M in 2014 (doubled since the merger), high double-digit growth and a presence in more than 25 countries. EndoChoice completed a successful IPO on June 5, 2015 and is traded, reflecting significant return to Accelmed.

 

new Endochoice case study

 

 

 

OIS – Platform Model Case Study

OIS is another example of the successful deployment of Accelmed’s Platform Model.

OIS, a California-based ophthalmic imaging systems player, acquired MediVision, the developer of an innovative retinal camera based on Israeli defense technology. The deal was financed and led by Accelmed, which held 44% of OIS’s shares post-merger in 2009. Within two years, OIS was sold, providing Accelmed with an outstanding return.

 

new OIS case study

 

 

 
 
 
 
 
 
 
 

Team

+
Mori Arkin
Co-Founder and Chairman of the Investment Committee
 
+
Dr. Uri Geiger
Co-Founder and Managing Partner
 
+
Dr. Irit Yaniv M.D., MBA
General Partner
 
+
Ilan Ben Oren
Partner & CTO
 
+
Amir Blatt
Partner
 
+
Lior Shav
Partner
 
+
Dr. Susan Alpert, M.D., Ph.D.
Chief Regulatory Officer
 
+
Dr. Gilad Rotem
Analyst
 
+
Nadav Shimoni
Analyst
 
 

Executives Network

 

Accelmed enjoys close collaboration with a network of seasoned executives who have built, led and sold companies for billions of dollars. These executives assist Accelmed in identifying and analyzing potential opportunities and may serve in key leadership roles in future platform companies.

 
 
 
 
 
 

The portfolio reflects a diversity of strategies employed in Accelmed’s first and second funds.

 

Cardiology & Structural Heart

+
Corvia
Corvia
 
+
Valcare Medical
Valcare Medical
 
+
Nitiloop
Nitiloop
 
+
Pi-Cardia
Pi-Cardia
 
 

Vascular & Peripheral

+
EndoSpan
EndoSpan
 
+
Eximo Medical
Eximo Medical
 
+
SoniVie
SoniVie
 
 

Orthopedics & Spine

+
MCS (Medical Compression Systems)
MCS (Medical Compression Systems)
 
+
NLT SPINE
NLT SPINE
 
+
CartiHeal
CartiHeal
 
 

GI and Metabolic Disease

+
Endochoice
Endochoice
 
+
Digma
Digma
 
 

Advanced Surgical Technologies

+
Memic
Memic
 
+
NitiNotes
NitiNotes
 
 

Sold Companies

+
Edge Medical Devices (sold)
Edge Medical Devices (sold)
 
+
PeerMedical (Merged with Endochoice)
PeerMedical (Merged with Endochoice)
 
+
Ophthalmic Imaging Systems (sold)
Ophthalmic Imaging Systems (sold)
 
+
Volcano (sold)
Volcano (sold)
 
 
Contact

6 Hachoshlim St. 6 floor
Herzliya Pituach, 46120
P.O.Box 2014
Tel | 972-9-7885599
Fax | 972-9-9588594
Email | info@accelmed.com